Andreas du Bois

Summary

Publications

  1. doi request reprint Fertility-sparing surgery in ovarian cancer: a systematic review
    Andreas du Bois
    Dept of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Germany
    Onkologie 36:436-43. 2013
  2. doi request reprint Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
    Andreas du Bois
    Gynäkologie and Gynäkologische Onkologie, Kliniken Essen Mitte, Essen, Germany
    Eur J Cancer 49:1905-14. 2013
  3. pmc Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
    A Du Bois
    Departments of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 Essen, Germany
    Br J Cancer 106:629-32. 2012
  4. doi request reprint Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer
    Andreas du Bois
    Arbeitsgemeinschaft Gynaekologische Onkologie AGO Studiengruppe, Germany
    Int J Gynecol Cancer 22:182-5. 2012
  5. doi request reprint A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Wiesbaden, Germany
    Ann Oncol 21:370-5. 2010
  6. doi request reprint Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    J Clin Oncol 28:4162-9. 2010
  7. doi request reprint Impact of treatment guidelines and implementation of a quality assurance program on quality of care in endometrial cancer
    Andreas du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Onkologie 32:493-8. 2009
  8. doi request reprint Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    Gynecol Oncol 112:422-36. 2009
  9. doi request reprint Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials
    Andreas du Bois
    Departments of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    J Clin Oncol 28:1733-9. 2010
  10. ncbi request reprint Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzin
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, HSK Wiesbaden, Germany AGO OVAR
    Cancer 115:1234-44. 2009

Collaborators

Detail Information

Publications43

  1. doi request reprint Fertility-sparing surgery in ovarian cancer: a systematic review
    Andreas du Bois
    Dept of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Germany
    Onkologie 36:436-43. 2013
    ..Available evidence on the prognostic impact of fertility-sparing surgery (FSS) is sparse, and there is an emerging need to consolidate such evidence...
  2. doi request reprint Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
    Andreas du Bois
    Gynäkologie and Gynäkologische Onkologie, Kliniken Essen Mitte, Essen, Germany
    Eur J Cancer 49:1905-14. 2013
    ..We therefore started a retrospective-prospective cohort study to better understand BOT and identify scenarios in which future studies could be developed...
  3. pmc Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
    A Du Bois
    Departments of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 Essen, Germany
    Br J Cancer 106:629-32. 2012
    ..Accordingly, this study evaluated the feasibility of combining pazopanib, an oral angiogenesis inhibitor, with paclitaxel and carboplatin...
  4. doi request reprint Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer
    Andreas du Bois
    Arbeitsgemeinschaft Gynaekologische Onkologie AGO Studiengruppe, Germany
    Int J Gynecol Cancer 22:182-5. 2012
    ....
  5. doi request reprint A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Wiesbaden, Germany
    Ann Oncol 21:370-5. 2010
    ....
  6. doi request reprint Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    J Clin Oncol 28:4162-9. 2010
    ..Gemcitabine was among the candidates for a third drug...
  7. doi request reprint Impact of treatment guidelines and implementation of a quality assurance program on quality of care in endometrial cancer
    Andreas du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Onkologie 32:493-8. 2009
    ..We evaluated the adherence to standard therapy before and after introduction of an internal quality management system and determined the reasons for non-adherence...
  8. doi request reprint Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    Gynecol Oncol 112:422-36. 2009
    ..This systematic review summarizes the available data evaluating the impact of different physician and hospital characteristics on outcome in ovarian cancer patients...
  9. doi request reprint Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials
    Andreas du Bois
    Departments of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    J Clin Oncol 28:1733-9. 2010
    ..The prognostic role of complete debulking has been well described; however, the impact of systematic pelvic and para-aortic lymphadenectomy and its interaction with biologic factors are still not fully defined...
  10. ncbi request reprint Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzin
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, HSK Wiesbaden, Germany AGO OVAR
    Cancer 115:1234-44. 2009
    ..However, the prognostic role of complete and so-called optimal and suboptimal debulking and its interaction with biological factors has not been not fully defined...
  11. pmc Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
    Silvia Darb-Esfahani
    Institute of Pathology, Charite Universitatsmedizin Berlin, Chariteplatz 1, Berlin, 10117, Germany
    Breast Cancer Res 11:R69. 2009
    ....
  12. doi request reprint Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)
    Pauline Wimberger
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen, Germany
    Ann Surg Oncol 17:1642-8. 2010
    ..The impact of surgical outcome on the survival of patients with International Federation of Gynecology and Obstetrics (FIGO) stage IV disease is less clear and is the subject of this study...
  13. doi request reprint Surgery for recurrent ovarian cancer
    Florian Heitz
    Department of Gynecology and Gynecological Oncology, Kliniken Essen Mitte, Huyssen Stiftung Knappschaft GmbH, Essen, Germany
    Womens Health (Lond Engl) 7:529-35. 2011
    ..In this article, further recent data regarding surgery for recurrent ovarian cancer are going to be discussed and the advantages of incorporating these patients into randomized trials are highlighted...
  14. doi request reprint Prognostic factors for complete debulking in first- and second-line ovarian cancer
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, Wiesbaden, Germany
    Int J Gynecol Cancer 19:S14-7. 2009
    ..Surgery is a mainstay of therapy in ovarian cancer. Are there any actual changes in the definitions and goals of surgery?..
  15. ncbi request reprint Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study G
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, HSK Dr Horst Schmidt Klinik Wiesbaden, Wiesbaden, Germany
    J Clin Oncol 24:1127-35. 2006
    ..One attempt to improve results could be the addition of non-cross-resistant drugs to platinum-paclitaxel combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens...
  16. doi request reprint Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer
    Jacek P Grabowski
    Department of Gynecology and Gynecological Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 Essen, Germany
    Gynecol Oncol 126:54-7. 2012
    ..Incomplete initial debulking occurs frequently in non-specialized centers and there is an ongoing discussion about the best time for re-surgery after referral to tertiary centers...
  17. doi request reprint Compliance to consensus recommendations, surgeon's experience, and introduction of a quality assurance and management program: influence on therapy of early-stage ovarian carcinoma
    Stefan Kommoss
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, HSK Wiesbaden, Wiesbaden, Germany
    Int J Gynecol Cancer 19:787-93. 2009
    ..Further outcome research should focus on methods for implementation of guidelines in daily practice in institutions caring for patients with ovarian carcinoma...
  18. ncbi request reprint Outcome of early breast cancer treated in an urban and a rural breast cancer unit in Germany
    Florian Heitz
    Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Evangelische Huyssen Stiftung Knappschafts GmbH, Essen, Germany
    Onkologie 36:477-82. 2013
    ..Conflicting evidence has been published concerning survival disadvantages in the outcome of breast cancer patients in relationship to their residency in urban or rural communities...
  19. doi request reprint Requirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activity
    Florian Heitz
    Department of Gynecology and Gynecologic Oncology, Evangelische Huyssens Stiftung, Kliniken Essen Mitte, Essen, Germany
    Clin Cancer Res 18:2632-7. 2012
    ..Logistic considerations, tissue sampling and tissue handling, and variability of a biomarker during surgery, in here PARP, were evaluated...
  20. doi request reprint Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, D 65199 Wiesbaden, Germany
    Expert Rev Anticancer Ther 10:81-8. 2010
    ..Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer...
  21. doi request reprint Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer
    Philipp Harter
    Dept of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany Dept of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Wiesbaden, Germany Electronic address
    Gynecol Oncol 132:537-41. 2014
    ..It is not defined whether the predictive value is independent from underlying tumor biology or is solely based on a selection of good prognostic risks...
  22. doi request reprint Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications
    Florian Heitz
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Int J Gynecol Cancer 20:41-6. 2010
    ..However, laparoscopy could induce tumor spread in ovarian cancer (OC). The aim of this study was to assess the incidence, the risk factors, and the complications of abdominal wall metastases (AWM) in patients with OC after laparoscopy...
  23. doi request reprint Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans Joachim Lück
    Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Breast Cancer Res Treat 139:779-87. 2013
    ..XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines. ..
  24. doi request reprint Differences in the receptor status between primary and recurrent breast cancer--the frequency of and the reasons for discordance
    Florian Heitz
    Department of Gynaecology and Gynaecologic Oncology, Evangelische Huyssens Stiftung, Kliniken Essen Mitte, Essen, Germany florian heitz gmx net
    Oncology 84:319-25. 2013
    ..Receptor discordances between primary and recurrent breast cancer have been described for years, but only a few analyses have elucidated the factors that influence receptor changes...
  25. ncbi request reprint Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study
    Ruth Gomez
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Int J Gynecol Cancer 19:1284-7. 2009
    ..This study analyzes the value of carboplatin skin testing and desensitization...
  26. doi request reprint Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG
    Florian Heitz
    Kliniken Essen Mitte, Evangelische Huyssens Stiftung, Department of Gynecology and Gynecologic Oncology, Henricistrasse 92, Essen, Germany
    Gynecol Oncol 129:463-6. 2013
    ..The aim of this study was to investigate the impact of medication with beta blocker in patients with recurrent ovarian cancer...
  27. doi request reprint Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, Wiesbaden, Germany
    Gynecol Oncol 121:615-9. 2011
    ..Therefore, introduction of quality management programs (QM) regarding the surgical therapy in ovarian cancer may help to improve outcome...
  28. ncbi request reprint Specialized pathology review in patients with ovarian cancer: results from a prospective study
    Stefan Kommoss
    Universitats Frauenklinik Tubingen, Germany AGO Study Group, Wiesbaden, Germany Philipps Universität Marburg, Koordinierungszentrum für Klinische Studien, Marburg, Germany Luzerner Kantonsspital, Institute of Pathology, Luzern, Switzerland Institute of Pathology, Dueren, Germany Horst Schmidt Kliniken HSK, Wiesbaden, Germany Institute of Pathology, Mannheim, Germany Gynecologic Oncology Center, Kiel, Germany and Department Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany
    Int J Gynecol Cancer 23:1376-82. 2013
    ..Finally, clinical trials may be biased through unintended disregard of histological inclusion criteria...
  29. doi request reprint Role of cytoreductive surgery in recurrent ovarian cancer
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    Expert Rev Anticancer Ther 9:917-22. 2009
    ..The surgical end point in recurrent ovarian cancer should be complete resection. Predictive factors could help identify patients in whom complete resection is possible...
  30. doi request reprint Bevacizumab in the treatment of ovarian cancer
    Florian Heitz
    Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Evangelische Huyssen Stiftung, Henricistrasse 92, 45136, Essen, Germany
    Adv Ther 29:723-35. 2012
    ..This finding led to the development in the 1990s of bevacizumab, a humanized monoclonal antibody against VEGF...
  31. doi request reprint Assessment of the sentinel lymph node in patients with invasive squamous carcinoma of the vulva
    Patriciu Achimas-Cadariu
    Deptartment of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Wiesbaden, Germany
    Acta Obstet Gynecol Scand 88:1209-14. 2009
    ..This study aims to evaluate the feasibility and diagnostic validity of the sentinel lymph node technique in detecting inguinal lymph node metastases in patients with invasive squamous cancer of the vulva...
  32. doi request reprint Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma
    Stefanie Scheil-Bertram
    Institute of Pathology and Cytology, HSK, Dr Horst Schmidt Klinik, Academic Teaching Hospital of University of Mainz, Wiesbaden, Germany
    Gynecol Oncol 119:325-31. 2010
    ..Therefore, we performed a retrospective study investigating ERCC1 expression and its correlation with patients' survival in OC...
  33. ncbi request reprint Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy
    Florian Heitz
    Department of Gynecology and Gynecological Oncology, Dr Horst Schmidt Kliniken HSK, Wiesbaden, Ludwig Erhard Str 100, 65199 Wiesbaden, Germany
    Expert Rev Anticancer Ther 10:1125-36. 2010
    ....
  34. ncbi request reprint Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistr 92, 45136, Essen, Germany
    Invest New Drugs 31:1499-504. 2013
    ..We aimed to establish a feasible combination therapy of PLD and vandetanib in ovarian cancer...
  35. ncbi request reprint Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik Wiesbaden, Ludwig Erhard Strasse 100, Wiesbaden, D 65199, Germany
    Ann Surg Oncol 13:1702-10. 2006
    ....
  36. ncbi request reprint A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    J Natl Cancer Inst 95:1320-9. 2003
    ..Therefore, we performed a randomized, phase III non-inferiority trial comparing paclitaxel plus cisplatin (PT) with paclitaxel plus carboplatin (TC) in patients with advanced ovarian cancer...
  37. doi request reprint Synchronous ovarian and endometrial cancer-an international multicenter case--control study
    Florian Heitz
    Department of Gynecology and Gynecologic Oncology, Evangelische Huyssens Stiftung Knappschaft GmbH, Kliniken Essen Mitte, Essen and Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Wiesbaden, Germany Department of Gynecologic Oncology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven Belgium Department of Gynecology, Charite, Campus Virchow Clinic University Hospital, Berlin Department of Gynecology and Obstetrics, Johannes Gutenberg University Mainz, Mainz Department of Gynecology and Obstetrics, University of Duisburg Essen, Essen Department of Gynecology and Obstetrics, Carl Gustav Carus University of Dresden, Dresden and Department of Pathology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    Int J Gynecol Cancer 24:54-60. 2014
    ..This study aimed to compare the prognosis of patients with synchronous endometrial and ovarian cancer (SEOC) to matched controls with either endometrial cancer (EC) or ovarian cancer (OC)...
  38. doi request reprint Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Int J Gynecol Cancer 21:289-95. 2011
    ..The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting...
  39. ncbi request reprint The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence
    Philipp Harter
    Department of Gynaecology and Gynaecologic Oncology HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, D 65199 Wiesbaden, Germany
    Curr Opin Oncol 17:505-14. 2005
    ..Some series have reported favorable outcomes for selected patients. This review summarizes the available evidence for selecting patients and the results of cytoreductive surgery in recurrent ovarian cancer...
  40. doi request reprint Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 prot
    Stefan Kommoss
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken HSK Wiesbaden, Ludwig Erhard Str 100, 65199, Wiesbaden, Germany
    Virchows Arch 454:249-56. 2009
    ..Alternative methods should be defined, which might help to separate patients with high risk of tumor progression from others with low risk...
  41. doi request reprint Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases
    Florian Heitz
    Department of Gynaecology and Gynaecological Oncology, EUSOMA Breast Unit, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, Wiesbaden D 65199, Germany
    Eur J Cancer 45:2792-8. 2009
    ..Evaluation of the influence of immunohistochemically defined breast cancer (BC) subtypes and other risk factors on the development of cerebral metastases (CM)...
  42. doi request reprint Surgery for relapsed ovarian cancer: when should it be offered?
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistr 92, 45136, Essen, Germany
    Curr Oncol Rep 14:539-43. 2012
    ..Clinical scores could help to identify suitable patients. Level I evidence is still missing; however, two randomized trials (DESKTOP III and GOG 213) are ongoing...
  43. ncbi request reprint BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer
    Annette Breuer
    Klinik für Gynäkologie und gynäkologische Onkologie, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Onkologie 30:316-8. 2007
    ..1% of all breast cancers) and is usually ER, PR, and HER2/neu negative by immunohistochemistry. A BRCA1 germline mutation in squamous cell breast cancer has never been reported...